RU2018114903A - Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии - Google Patents
Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии Download PDFInfo
- Publication number
- RU2018114903A RU2018114903A RU2018114903A RU2018114903A RU2018114903A RU 2018114903 A RU2018114903 A RU 2018114903A RU 2018114903 A RU2018114903 A RU 2018114903A RU 2018114903 A RU2018114903 A RU 2018114903A RU 2018114903 A RU2018114903 A RU 2018114903A
- Authority
- RU
- Russia
- Prior art keywords
- masp
- antibody
- pharmaceutical composition
- inhibiting
- composition according
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims 19
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 title claims 18
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 title claims 18
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 title claims 11
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 title claims 11
- 239000000203 mixture Substances 0.000 title claims 4
- 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 title claims 2
- 201000001505 hemoglobinuria Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 7
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Фармацевтическая композиция, содержащая по меньшей мере одно антитело, ингибирующее путь комплемента, или его антигенсвязывающий фрагмент, где по меньшей мере одно ингибирующее антитело или его антигенсвязывающий фрагмент содержит антитело, ингибирующее MASP-2, или его фрагмент, и антитело, ингибирующее MASP-3, или его фрагмент, и фармацевтически приемлемый носитель, где указанная композиция ингибирует оба из лектинового пути и альтернативного пути комплемента.
2. Фармацевтическая композиция по п.1, где по меньшей мере одно ингибирующее антитело содержит комбинацию первого антитела, являющегося антителом, ингибирующим MASP-3, и второго антитела, являющегося антителом, ингибирующим MASP-2.
3. Фармацевтическая композиция по п.1, где по меньшей мере одно ингибирующее антитело содержит одно антитело, имеющее активность в качестве антитела, ингибирующего MASP-3, и активность в качестве антитела, ингибирующего MASP-2.
4. Фармацевтическая композиция по п.1, где антителом, ингибирующим MASP-3, является моноклональное антитело против MASP-3 или его фрагмент.
5. Фармацевтическая композиция по п.1, где антителом, ингибирующим MASP-2, является моноклональное антитело против MASP-2 или его фрагмент.
6. Фармацевтическая композиция по п.1, где антитело, ингибирующее MASP-3, ингибирует созревание фактора D.
7. Фармацевтическая композиция по п.1, где антитело, ингибирующее MASP-3, специфически связывается с частью MASP-3 (SEQ ID NO: 8: полноразмерной).
8. Фармацевтическая композиция по п.1, где антитело, ингибирующее MASP-3, специфически связывается с частью MASP-3 с аффинностью по меньшей мере в 10 раз выше, чем при связывании с MASP-1 (SEQ ID NO: 10).
9. Фармацевтическая композиция по п.8, где антитело, ингибирующее MASP-3, специфически связывается с доменом сериновой протеазы MASP-3 (а/к 450-711 в SEQ ID NO: 8).
10. Фармацевтическая композиция по п.1, где антитело, ингибирующее MASP-3, также связывается с частью MASP-2 (SEQ ID NO: 5).
11. Фармацевтическая композиция по п.10, где антителом, ингибирующим MASP-3, является двойной ингибитор MASP-2/MASP-3, связывающийся с консервативной областью в доменах сериновой протеазы MASP-2 и MASP-3.
12. Фармацевтическая композиция по п.10, где антителом, ингибирующим MASP-3, является биспецифическое моноклональное антитело, связывающееся с доменом сериновой протеазы MASP-3 (а/к 450-711 в SEQ ID NO: 8), а также связывающееся по меньшей мере с одним из домена сериновой протеазы MASP-2 (а/к 445-682 в SEQ ID NO: 5) или домена CCP-1-CCP2 MASP-2 (а/к 300-431 в SEQ ID NO: 5).
13. Фармацевтическая композиция по п.1, где композиция дополнительно содержит антитело против MASP-3 и антитело против MASP-2.
14. Фармацевтическая композиция по п.1, где антитело или его фрагмент выбраны из группы, состоящей из рекомбинантного антитела, антитела со сниженной эффекторной функцией, химерного и гуманизированного антитела или антитела человека.
15. Фармацевтическая композиция по п.1, где композиция составлена для подкожной, внутримышечной, внутривенной, внутриартериальной доставки или в виде ингалянта.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621461P | 2012-04-06 | 2012-04-06 | |
| US61/621,461 | 2012-04-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014144621A Division RU2655299C2 (ru) | 2012-04-06 | 2013-04-05 | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018114903A true RU2018114903A (ru) | 2019-03-04 |
| RU2018114903A3 RU2018114903A3 (ru) | 2021-08-12 |
Family
ID=49325295
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018114903A RU2018114903A (ru) | 2012-04-06 | 2013-04-05 | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии |
| RU2014144621A RU2655299C2 (ru) | 2012-04-06 | 2013-04-05 | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014144621A RU2655299C2 (ru) | 2012-04-06 | 2013-04-05 | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20130273053A1 (ru) |
| EP (2) | EP3366307B1 (ru) |
| JP (3) | JP6366571B2 (ru) |
| KR (2) | KR102142508B1 (ru) |
| CN (1) | CN104661676A (ru) |
| AU (3) | AU2013267909B2 (ru) |
| BR (1) | BR112014024793A2 (ru) |
| CA (2) | CA3087933A1 (ru) |
| CL (1) | CL2014002694A1 (ru) |
| CY (1) | CY1120736T1 (ru) |
| DK (2) | DK2833907T3 (ru) |
| ES (2) | ES2670668T3 (ru) |
| HK (1) | HK1206996A1 (ru) |
| HR (1) | HRP20180671T1 (ru) |
| HU (1) | HUE036930T2 (ru) |
| IL (2) | IL234991B (ru) |
| IN (1) | IN2014KN02324A (ru) |
| LT (1) | LT2833907T (ru) |
| MX (2) | MX357540B (ru) |
| NO (1) | NO2881536T3 (ru) |
| NZ (2) | NZ781091A (ru) |
| PL (2) | PL3366307T3 (ru) |
| PT (1) | PT2833907T (ru) |
| RS (1) | RS57266B1 (ru) |
| RU (2) | RU2018114903A (ru) |
| SI (1) | SI2833907T1 (ru) |
| TR (1) | TR201806939T4 (ru) |
| WO (1) | WO2013180834A2 (ru) |
| ZA (1) | ZA201408100B (ru) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3131223C (en) * | 2011-05-04 | 2024-01-30 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| EP3058951A1 (en) * | 2012-06-18 | 2016-08-24 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| CA2906096C (en) | 2013-03-15 | 2022-03-15 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| WO2018097307A1 (ja) * | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| TW202235438A (zh) | 2016-11-28 | 2022-09-16 | 日商中外製藥股份有限公司 | 能夠調節配體結合活性的配體結合分子 |
| US11827717B2 (en) | 2017-04-03 | 2023-11-28 | Chugai Seiyaku Kabushiki Kaisha | Anti-MASP-1 antibodies and methods of use |
| WO2019107380A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| BR112020024148A2 (pt) * | 2018-05-29 | 2021-03-30 | Omeros Corporation | Compostos, composição farmacêutica, e, métodos para identificação de uma pequena molécula capaz de inibir masp-2 e para o tratamento de uma doença ou transtorno associado a masp-2 |
| WO2019230867A1 (en) | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| MX2022001268A (es) * | 2019-07-31 | 2022-02-22 | Biocryst Pharm Inc | Regimenes de dosificacion para inhibidores orales del factor d del complemento. |
| WO2021113698A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| JP2023504543A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| CA3159176A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
| CN114295594B (zh) * | 2021-12-06 | 2023-09-19 | 贵州理工学院 | 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| RU2002113381A (ru) * | 1999-12-02 | 2004-01-27 | Дженс Христиан ДЖЕНСЕНИУС (DK) | MASP-3, комплемент-связывающий фермент и его применение |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US7043719B2 (en) * | 2001-07-23 | 2006-05-09 | Intel Corporation | Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations |
| JP4723244B2 (ja) | 2002-07-19 | 2011-07-13 | オメロス コーポレイション | 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料 |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| US20060140939A1 (en) * | 2003-02-21 | 2006-06-29 | Fung Sek C M | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| EP1713929A2 (en) * | 2004-02-03 | 2006-10-25 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP2495257A3 (en) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ATE419671T1 (de) * | 2006-07-31 | 2009-01-15 | Fiat Ricerche | Durch eine fluidströmung betätigbarer elektrischer generator |
| ES2628973T3 (es) | 2007-05-31 | 2017-08-04 | University Of Washington | Mutagénesis inducible de genes diana |
| EP2342231A1 (en) * | 2008-09-26 | 2011-07-13 | Roche Glycart AG | Bispecific anti-egfr/anti-igf-1r antibodies |
| AU2010203712A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| BRPI1010534A2 (pt) * | 2009-03-05 | 2016-03-15 | Smith & Nephew Inc | sistema, método e aparelho para colocação de um fio guia no colo femoral |
| KR101870378B1 (ko) * | 2009-07-17 | 2018-06-25 | 릭스하스피탈렛 | 보체 활성화의 억제제로서의 ｍａｓｐ 이소형 |
| EP2496259B1 (en) * | 2009-11-05 | 2017-02-22 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria |
| CA3076975C (en) * | 2011-04-08 | 2024-06-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
-
2013
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/en active Active
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 CA CA3087933A patent/CA3087933A1/en active Pending
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/en active Application Filing
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/en active
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active IP Right Grant
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/en active Active
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 CA CA2869326A patent/CA2869326C/en active Active
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active IP Right Grant
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 MX MX2018008658A patent/MX2018008658A/es unknown
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
-
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
-
2015
- 2015-08-10 HK HK15107717.0A patent/HK1206996A1/xx unknown
-
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-04-26 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
-
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
-
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018114903A (ru) | Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии | |
| HRP20210559T1 (hr) | Pripravci i postupci inhibiranja masp-1 i/ili masp-2 i/ili masp-3 za liječenje raznih bolesti i poremećaja | |
| HRP20201733T1 (hr) | Postupci liječenja stanja povezanih s aktivacijom komplementa ovisnim o masp-2 | |
| RU2020120539A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| JP2015532644A5 (ru) | ||
| RS54685B1 (en) | ANTI-N3pGlu AMILOID BETA PEPTID ANTIBODIES AND THEIR USES | |
| IL248392B2 (en) | Human antibodies to Middle East respiratory syndrome coronavirus spike protein | |
| JP2015504421A5 (ru) | ||
| EP3565835A1 (en) | Human antibodies to s.aureus hemolysin a toxin | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| NZ617298A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| WO2006110214A3 (en) | Antibodies against mammalian metapneumovirus | |
| NZ732970A (en) | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ630881A (en) | Use of semaphorin-4d binding molecules for treatment of atherosclerosis | |
| ES2570153T3 (es) | Anticuerpos anti-C5aR con propiedades mejoradas | |
| WO2012139069A3 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
| RU2017144629A (ru) | Тромбин-связывающие молекулы антител и их применение | |
| MX2021000889A (es) | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. | |
| RU2017120031A (ru) | Способ лечения или предотвращения инсульта |